Thalia Therapeutics
RNA-based therapeutics and delivery tech for oncology and cardiovascular disease
- Category
- Other
- Launched
- June 26, 2026
- Stage
- Series Unknown
- Founder
- Dr. David Solomon
- Website
- thaliatx.com
Thalia Therapeutics is a British biotechnology company developing RNA based therapeutics and proprietary delivery technologies. Its platform, Nuvec®, uses amorphous silica nanoparticles with an irregular surface structure to trap and protect RNA, enabling multi RNA loading, flexible targeting, and potential oral delivery. The company's pipeline includes a dual target cardiovascular siRNA programme for atherosclerotic cardiovascular disease (ASCVD) and a clinical stage microRNA therapeutic candidate, miRisten, for Acute Myeloid Leukaemia, acquired through the acquisition of Sanmirna Therapeutics alongside a €3.1 million raise.
Discovered via